Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; 1 of the 6 sources its claims cite were checked for support.

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Open access

Abstract

BACKGROUND: Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnosed multiple myeloma is needed. METHODS: In this phase 3 trial, we randomly assigned 709 transplantation-eligible patients with newly diagnosed multiple myeloma to receive either subcutaneous daratumumab combined with VRd induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd group) or VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group). The primary end point was progression-free survival. Key secondary end points were a complete response or better and minimal residual disease (MRD)-negative status. RESULTS: At a median follow-up of 47.5 months, the risk of disease progression or death in the D-VRd group was lower than the risk in the VRd group. The estimated percentage of patients with progression-free survival at 48 months was 84.3% in the D-VRd group and 67.7% in the VRd group (hazard ratio for disease progression or death, 0.42; 95% confidence interval, 0.30 to 0.59; P<0.001); the P value crossed the prespecified stopping boundary (P = 0.0126). The percentage of patients with a complete response or better was higher in the D-VRd group than in the VRd group (87.9% vs. 70.1%, P<0.001), as was the percentage of patients with MRD-negative status (75.2% vs. 47.5%, P<0.001). Death occurred in 34 patients in the D-VRd group and 44 patients in the VRd group. Grade 3 or 4 adverse events occurred in most patients in both groups; the most common were neutropenia (62.1% with D-VRd and 51.0% with VRd) and thrombocytopenia (29.1% and 17.3%, respectively). Serious adverse events occurred in 57.0% of the patients in the D-VRd group and 49.3% of those in the VRd group. CONCLUSIONS: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. (Funded by the European Myeloma Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov number, NCT03710603; EudraCT number, 2018-002992-16.).

Overview

CoChat Summary

## TL;DR

The supplementary appendix for the PERSEUS trial describes a randomized comparison of subcutaneous daratumumab plus bortezomib/lenalidomide/dexamethasone (D-VRd) versus VRd alone in transplant-eligible patients with newly diagnosed multiple myeloma. It mainly provides endpoint definitions, statistical methods, eligibility criteria, subgroup results, and safety tables, but not the full primary efficacy narrative.

## Key findings

  • The trial’s primary endpoint was progression-free survival; key secondary endpoints were overall complete response or better, overall minimal residual disease (MRD)-negativity, and overall survival.
  • At the interim analysis, the primary endpoint was tested at an exact two-sided significance level of 0.0126, determined by 153 progression-free survival events under an Hwang-Shih-DeCani alpha-spending function.
  • In prespecified subgroup analyses, D-VRd showed higher overall complete response or better rates and MRD-negativity rates across most reported subgroups; for example, MRD-negativity was 71.1% vs 45.9% in men, 81.3% vs 49.7% in women, and 78.2% vs 46.8% in patients younger than 65 years.
  • Safety tables report serious adverse events in 57.0% of D-VRd patients (200/351) versus 49.3% of VRd patients (171/347); infections were the most common serious adverse event category (35.0% vs 27.4%).

## Methods

  • Randomized PERSEUS study in transplant-eligible patients with newly diagnosed multiple myeloma; eligible patients were 18 to 70 years old and had ECOG performance status 0 to 2 and specified laboratory/organ-function criteria.
  • The appendix specifies an intention-to-treat framework for efficacy endpoints and a safety population of patients who received at least one dose of study treatment; sample sizes in the safety tables were 351 for D-VRd and 347 for VRd.
  • Main analyses included progression-free survival with two interim analyses and a final analysis, plus hierarchical testing of key secondary endpoints to control family-wise type I error; subgroup analyses are shown for complete response or better and MRD-negativity.

## Limitations

  • The appendix text itself does not report the main trial’s headline efficacy results (for example, hazard ratios or median progression-free survival), so those outcomes cannot be summarized from this text alone.
  • The subgroup forest plots note that the widths of confidence intervals were not adjusted for multiplicity and cannot be used to infer treatment effects.
  • Evident from the provided text: this is a supplementary appendix only, so it is incomplete as a standalone paper summary.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2312054

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure S1 Trial Design.
Figure S1 Trial Design.From the PDF
Figure S2 CONSORT Patient Flow Diagram.
Figure S2 CONSORT Patient Flow Diagram.From the PDF
Image 3
From the PDF

Verification

Claims the paper makes

1 Valid · 1 Not valid · 3 Not checked · 42 Own results and interpretations

24 more claims

Create a free account to see all 47 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 10
  • It may state two separate claims as one. 11
  • The quote only partly states this claim. 3

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 599

Metadata

Authors
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., Perrot, A., Cavo, M., Belotti, A., Broijl, A., Gay, F., Mina, R., Nijhof, I. S., van de Donk, N. W. C. J., Katodritou, E., Schjesvold, F., Sureda Balari, A., Rosiñol, L., Delforge, M., Roeloffzen, W., Silzle, T., Vangsted, A., Einsele, H., Spencer, A., Hajek, R., Jurczyszyn, A., Lonergan, S., Ahmadi, T., Liu, Y., Wang, J., Vieyra, D., van Brummelen, E. M. J., Vanquickelberghe, V., Sitthi-Amorn, A., de Boer, C. J., Carson, R., Rodriguez-Otero, P., Bladé, J., & Moreau, P.
Affiliations
  • University Medical Center Groningen (NL)
  • The University of Sydney (AU)
  • From the Department of Hematology, Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) — all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) — both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi ...
  • Oslo University Hospital (NO)
  • Jagiellonian University (PL)
Venue
New England Journal of Medicine
Published
2024-01-25
Volume
390
Issue
4
Pages
301-313
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4389606680
Cited by
599
References
23
Citations by year
2026: 198 · 2025: 252 · 2024: 145
FWCI
123.04
Type
journal article
Language
en
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • Lirias (KU Leuven) (submittedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
Funders
European Myeloma Network in collaboration with Janssen Research & Development, LLC
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
multiple myeloma, daratumumab, bortezomib, lenalidomide, dexamethasone, subcutaneous daratumumab, CD38, newly diagnosed multiple myeloma, progression-free survival, minimal residual disease, complete response, lenalidomide maintenance, neutropenia
MeSH terms
Bortezomib, Lenalidomide, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Membrane Glycoproteins, Multiple Myeloma, Disease Progression, ADP-ribosyl Cyclase 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. https://app.cochat.ai/papers/10.1056/nejmoa2312054
The paper
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., Perrot, A., Cavo, M., Belotti, A., Broijl, A., Gay, F., Mina, R., Nijhof, I. S., van de Donk, N. W. C. J., Katodritou, E., . . . Moreau, P. (2024). Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2312054

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.